Amedeo Smart

Free Medical Literature Service


 

Amedeo

Prostate Cancer

  Free Subscription

Articles published in
Oncogene
    September 2025
  1. SHENG H, Shi G, Lu Y, Zheng S, et al
    KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in prostate cancer.
    Oncogene. 2025 Sep 23. doi: 10.1038/s41388-025-03576.
    >> Share

  2. GE Y, Han P, Sun Y, Chen Y, et al
    Aging-associated ZNF573 methylation regulates RNF19B-PIK3CA ubiquitination to promote prostate cancer.
    Oncogene. 2025 Sep 19. doi: 10.1038/s41388-025-03579.
    >> Share

  3. CHUKHU M, Dahiya UR, Heemers HV
    Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer.
    Oncogene. 2025 Sep 18. doi: 10.1038/s41388-025-03573.
    >> Share

  4. RAZA M, Rajan AR, Kennedy BB, Reznicek TE, et al
    ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by regulating glycolysis.
    Oncogene. 2025 Sep 4. doi: 10.1038/s41388-025-03559.
    >> Share

  5. CIVENNI G, Sandrini G, Merulla J, Musumeci C, et al
    Integrated control of cancer stemness by sigma(1) receptor in advanced prostate cancer.
    Oncogene. 2025 Sep 2. doi: 10.1038/s41388-025-03541.
    >> Share

    August 2025
  6. TONG T, Lei H, Huang M, Yang Z, et al
    HOMER3 orchestrates SRC-YAP1 activity that promotes tumor cell growth and antagonizes anti-tumor immunotherapy in prostate cancer.
    Oncogene. 2025 Aug 23. doi: 10.1038/s41388-025-03548.
    >> Share

  7. ANDRIEU C, Taieb D, Baylot V, Ettinger S, et al
    Correction: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
    Oncogene. 2025 Aug 7. doi: 10.1038/s41388-025-03531.
    >> Share

  8. HAO JL, He JQ, Hu H, Zhu ZH, et al
    TLL1 knockdown attenuates prostate cancer progression by enhancing antitumor immunity.
    Oncogene. 2025 Aug 4. doi: 10.1038/s41388-025-03517.
    >> Share

  9. SANCHIS P, Sabater A, Lechuga J, Rada J, et al
    PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression.
    Oncogene. 2025 Aug 2. doi: 10.1038/s41388-025-03511.
    >> Share

    July 2025
  10. HUO D, Si M, Yu K, Fang X, et al
    Increased antiandrogen enzalutamide sensitivity via altering prostate cancer stem cell traits through modulating the androgen receptor-mediated CDR1/circCDR1-AS/miR-1290/BMP4 signaling.
    Oncogene. 2025 Jul 4. doi: 10.1038/s41388-025-03482.
    >> Share

    April 2025
  11. WALKE P, Price JDW, Vizeacoumar FS, Joseph N, et al
    A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer.
    Oncogene. 2025 Apr 29. doi: 10.1038/s41388-025-03413.
    >> Share

  12. ANDRIEU C, Taieb D, Baylot V, Ettinger S, et al
    Editorial Expression of Concern: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
    Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03407.
    >> Share

  13. YANG JC, Xu P, Ning S, Wasielewski LJ, et al
    Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
    Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03392.
    >> Share

    March 2025
  14. HOFSTAD M, Woods A, Parra K, Sychev ZE, et al
    Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer.
    Oncogene. 2025 Mar 21. doi: 10.1038/s41388-025-03343.
    >> Share

  15. YIN L, Dai Y, Wang Y, Liu S, et al
    A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR transcriptional activity in prostate cancer cells.
    Oncogene. 2025 Mar 6. doi: 10.1038/s41388-025-03328.
    >> Share

  16. SCHMIDT MJ, Naghdloo A, Prabakar RK, Kamal M, et al
    Polyploid cancer cells reveal signatures of chemotherapy resistance.
    Oncogene. 2025;44:439-449.
    >> Share

    January 2025
  17. KAUSHAL JB, Raut P, Halder S, Alsafwani ZW, et al
    Oncogenic potential of truncated-Gli3 via the Gsk3beta/Gli3/AR-V7 axis in castration-resistant prostate cancer.
    Oncogene. 2025 Jan 16. doi: 10.1038/s41388-024-03266.
    >> Share

    December 2024
  18. DUTTA S, Khedmatgozar H, Patel GK, Latour D, et al
    A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer.
    Oncogene. 2024 Dec 20. doi: 10.1038/s41388-024-03252.
    >> Share

  19. WOYTASH JA, Kumar R, Chaudhary AK, Donnelly C, et al
    Mitochondrial unfolded protein response-dependent beta-catenin signaling promotes neuroendocrine prostate cancer.
    Oncogene. 2024 Dec 17. doi: 10.1038/s41388-024-03261.
    >> Share

    November 2024
  20. HUANG F, Li K, Chen Z, Cui Z, et al
    Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer.
    Oncogene. 2024 Nov 29. doi: 10.1038/s41388-024-03239.
    >> Share

  21. RODRIGUES SOUSA E, de Brot S, Zoni E, Zeinali S, et al
    CRIPTO's multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data.
    Oncogene. 2024 Nov 26. doi: 10.1038/s41388-024-03230.
    >> Share

  22. LYU C, Vaddi PK, Elshafae S, Pradeep A, et al
    Unveiling RACK1: a key regulator of the PI3K/AKT pathway in prostate cancer development.
    Oncogene. 2024 Nov 13. doi: 10.1038/s41388-024-03224.
    >> Share

  23. SHARMA S, Pei X, Xing F, Wu SY, et al
    Correction: Regucalcin promotes dormancy of prostate cancer.
    Oncogene. 2024 Nov 11. doi: 10.1038/s41388-024-03216.
    >> Share

  24. TAHSIN S, Sane NS, Cernyar B, Jiang L, et al
    Correction: AR loss in prostate cancer stroma mediated by NF-kappaB and p38-MAPK signaling disrupts stromal morphogen production.
    Oncogene. 2024 Nov 7. doi: 10.1038/s41388-024-03190.
    >> Share

  25. OFFENHAUSER C, Dave KA, Beckett KJ, Smith FM, et al
    EphA2 regulates vascular permeability and prostate cancer metastasis via modulation of cell junction protein phosphorylation.
    Oncogene. 2024 Nov 7. doi: 10.1038/s41388-024-03206.
    >> Share

  26. HUANG H, Zhuang X, Yin S, Sun W, et al
    The Ku70-SIX1-GPT2 axis regulates alpha-ketoglutarate metabolism to drive progression of prostate cancer.
    Oncogene. 2024 Nov 2. doi: 10.1038/s41388-024-03209.
    >> Share

  27. RHEE JW, Adzavon YM, Sun Z
    Stromal androgen signaling governs essential niches in supporting prostate development and tumorigenesis.
    Oncogene. 2024;43:3419-3425.
    >> Share

    October 2024
  28. WANG K, Chen M, Yan S, Han Y, et al
    Zinc ions activate AKT and promote prostate cancer cell proliferation via disrupting AKT intramolecular interaction.
    Oncogene. 2024 Oct 23. doi: 10.1038/s41388-024-03195.
    >> Share

  29. LIN G, Tian F, Yu Q, Weng X, et al
    IL-17RA/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer growth.
    Oncogene. 2024 Oct 18. doi: 10.1038/s41388-024-03169.
    >> Share

  30. XIONG X, Zhang S, Zhu W, Du J, et al
    Androgen-ablative therapies inducing CXCL8 regulates mTORC1/SREBP2-dependent cholesterol biosynthesis to support progression of androgen receptor negative prostate cancer cells.
    Oncogene. 2024 Oct 5. doi: 10.1038/s41388-024-03181.
    >> Share

    September 2024
  31. MU Y, Wallenius A, Zang G, Zhu S, et al
    The TbetaRI promotes migration and metastasis through thrombospondin 1 and ITGAV in prostate cancer cells.
    Oncogene. 2024 Sep 20. doi: 10.1038/s41388-024-03165.
    >> Share

  32. SARDAR S, McNair CM, Ravindranath L, Chand SN, et al
    AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
    Oncogene. 2024 Sep 13. doi: 10.1038/s41388-024-03148.
    >> Share

    August 2024
  33. YU J, Zhang M, Li T, Gao W, et al
    Monoacylglycerol lipase blockades the senescence-associated secretory phenotype by interfering with NF-kappaB activation and promotes docetaxel efficacy in prostate cancer.
    Oncogene. 2024 Aug 18. doi: 10.1038/s41388-024-03132.
    >> Share

  34. XIONG S, Li S, Li Z, Song Y, et al
    A noncanonical E3 ubiquitin ligase RNF41-mediated MYO1C stability promotes prostate cancer metastasis by inducing actin remodeling.
    Oncogene. 2024 Aug 7. doi: 10.1038/s41388-024-03120.
    >> Share

    July 2024
  35. JIN Z, Wang H, Tang R, Pan B, et al
    GATA2 promotes castration-resistant prostate cancer development by suppressing IFN-beta axis-mediated antitumor immunity.
    Oncogene. 2024 Jul 27. doi: 10.1038/s41388-024-03107.
    >> Share

    June 2024
  36. LIN G, Zhang F, Weng X, Hong Z, et al
    Role of gut microbiota in the pathogenesis of castration-resistant prostate cancer: a comprehensive study using sequencing and animal models.
    Oncogene. 2024 Jun 17. doi: 10.1038/s41388-024-03073.
    >> Share

  37. CHEN B, Xu P, Yang JC, Nip C, et al
    Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer.
    Oncogene. 2024 Jun 14. doi: 10.1038/s41388-024-03081.
    >> Share

  38. FRANCIS JC, Capper A, Rust AG, Ferro K, et al
    Identification of genes that promote PI3K pathway activation and prostate tumour formation.
    Oncogene. 2024;43:1824-1835.
    >> Share

    May 2024
  39. ZHAO J, Shen J, Mao L, Yang T, et al
    Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer.
    Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03057.
    >> Share

  40. TAHSIN S, Sane NS, Cernyar B, Jiang L, et al
    AR loss in prostate cancer stroma mediated by NF-kappaB and p38-MAPK signaling disrupts stromal morphogen production.
    Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03064.
    >> Share

  41. BEIER AK, Ebersbach C, Siciliano T, Scholze J, et al
    Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer.
    Oncogene. 2024 May 15. doi: 10.1038/s41388-024-03059.
    >> Share

    April 2024
  42. RAWAT C, Heemers HV
    Alternative splicing in prostate cancer progression and therapeutic resistance.
    Oncogene. 2024 Apr 24. doi: 10.1038/s41388-024-03036.
    >> Share

  43. ARRIAGA JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al
    Correction: In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.
    Oncogene. 2024 Apr 16. doi: 10.1038/s41388-024-03031.
    >> Share

  44. LI Y, Lv L, Ye M, Xie N, et al
    PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression.
    Oncogene. 2024 Apr 8. doi: 10.1038/s41388-024-03024.
    >> Share

  45. CHEN M, Zou C, Tian Y, Li W, et al
    An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer.
    Oncogene. 2024 Apr 2. doi: 10.1038/s41388-024-03011.
    >> Share

    March 2024
  46. YI Q, Han X, Yu HG, Chen HY, et al
    SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.
    Oncogene. 2024 Mar 26. doi: 10.1038/s41388-024-02944.
    >> Share

  47. GUO S, Miao M, Wu Y, Pan D, et al
    DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer.
    Oncogene. 2024 Mar 13. doi: 10.1038/s41388-024-03005.
    >> Share

  48. ARRIAGA JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al
    In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.
    Oncogene. 2024 Mar 7. doi: 10.1038/s41388-024-02995.
    >> Share

  49. LI J, Hong Z, Zhang J, Zheng S, et al
    Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.
    Oncogene. 2024;43:744-757.
    >> Share

    January 2024
  50. CHAO Y, Chen Y, Zheng W, Demanelis K, et al
    Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer.
    Oncogene. 2024 Jan 25. doi: 10.1038/s41388-024-02939.
    >> Share

  51. RODRIGUEZ TIRADO C, Wang C, Li X, Deng S, et al
    UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance.
    Oncogene. 2024;43:265-280.
    >> Share

    December 2023
  52. FERRARI MG, Jimenez-Uribe AP, Wang L, Hoeppner LH, et al
    Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.
    Oncogene. 2023 Dec 23. doi: 10.1038/s41388-023-02925.
    >> Share

  53. MILLER KA, Degan S, Wang Y, Cohen J, et al
    Correction: PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02920.
    >> Share

  54. CHAUHAN SS, Casillas AL, Vizzerra AD, Liou H, et al
    PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02914.
    >> Share

    November 2023
  55. EIGENTLER A, Handle F, Schanung S, Degen A, et al
    Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts.
    Oncogene. 2023 Nov 29. doi: 10.1038/s41388-023-02901.
    >> Share

  56. CUI H, Wang Y, Zhou T, Qu L, et al
    Targeting DGAT1 inhibits prostate cancer cells growth by inducing autophagy flux blockage via oxidative stress.
    Oncogene. 2023 Nov 16. doi: 10.1038/s41388-023-02878.
    >> Share

    October 2023
  57. MILLER KA, Degan S, Wang Y, Cohen J, et al
    PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Oncogene. 2023 Oct 24. doi: 10.1038/s41388-023-02875.
    >> Share

    September 2023
  58. ADVANI R, Luzzi S, Scott E, Dalgliesh C, et al
    Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer.
    Oncogene. 2023 Sep 26. doi: 10.1038/s41388-023-02838.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016